Back to Search Start Over

Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study

Authors :
Gérard Slama
Hubert Vidal
Valeria Pechtner
Geraldine Skurnik
Michèle Guerre-Millo
Karine Clément
Emmanuelle Meugnier
Sophie Rome
Annie Quignard-Boulangé
Morvarid Kabir
Nadia Naour
Salwa W. Rizkalla
Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN)
Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon)
Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Physiologie de la Nutrition et du Comportement Alimentaire (PNCA)
Institut National de la Recherche Agronomique (INRA)-AgroParisTech
Hôpital Hôtel Dieu
Assistance Publique-Hôpitaux de Paris (AP-HP)
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN)
Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
Nutrition, métabolisme, obésité: aspect cellulaire et moléculaire
Institut National de la Santé et de la Recherche Médicale (INSERM)
Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon)
Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Institut National de la Recherche Agronomique (INRA)
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN)
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
AgroParisTech-Institut National de la Recherche Agronomique (INRA)
Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]
Source :
ResearcherID, The American Journal of Clinical Nutrition, The American Journal of Clinical Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩, American Journal of Clinical Nutrition, American Journal of Clinical Nutrition, American Society for Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩

Abstract

Background: Information is lacking on the potential effect of n3 polyunsaturatedfattyacids(PUFAs)ontheadiposetissueofpatients with type 2 diabetes. Objective: We evaluated whether n3 PUFAs have additional effects on adiposity, insulin sensitivity, adipose tissue function (production of adipokines and inflammatory and atherogenic factors), and gene expression in type 2 diabetes. Design: Twenty-seven women with type 2 diabetes without hypertriglyceridemia were randomly allocated in a double-blind parallel design to 2 mo of 3 g/d of either fish oil (1.8 g n3 PUFAs) or placebo (paraffin oil). Results: Although body weight and energy intake measured by use of a food diary were unchanged, total fat mass (P 0.019) and subcutaneous adipocyte diameter (P 0.0018) were lower in the fish oil group than in the placebo group. Insulin sensitivity was not significantlydifferentbetweenthe2groups(measuredbyhomeostasis model assessment in all patients and by euglycemichyperinsulinemic clamp in a subgroup of 5 patients per group). By contrast, atherogenic risk factors, including plasma triacylglycerol (P 0.03), the ratio of triacylglycerol to HDL cholesterol (atherogenic index, P 0.03), and plasma plasminogen activator inhibitor-1 (P 0.01), were lower in the fish oil group than in the placebo group. In addition, a subset of inflammation-related genes wasreducedinsubcutaneousadiposetissueafterthefishoil,butnot the placebo, treatment. Conclusions: A moderate dose of n3 PUFAs for 2 mo reduced adiposity and atherogenic markers without deterioration of insulin sensitivity in subjects with type 2 diabetes. Some adipose tissue inflammation-related genes were also reduced. These beneficial effects could be linked to morphologic and inflammatory changes in adipose tissue. This trial was registered at clinicaltrials.gov as NCT0037. Am J Clin Nutr 2007;86:1670–9.

Details

ISSN :
00029165 and 19383207
Database :
OpenAIRE
Journal :
ResearcherID, The American Journal of Clinical Nutrition, The American Journal of Clinical Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩, American Journal of Clinical Nutrition, American Journal of Clinical Nutrition, American Society for Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩
Accession number :
edsair.doi.dedup.....6b0b0a37373ffbf910594411cf39a703
Full Text :
https://doi.org/10.1093/ajcn/86.5.1670⟩